Physician profile
Ariele Pollack
NPI 1386256154
$13,780.07
in general payments reported to CMS, 2019-2025
57 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,719 · 2022: $3,054 · 2023: $2,705 · 2024: $2,714 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,479 · Education: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,479.37 |
| Education | $527.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,262.65 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $1,102.31 | 2021-2025 | Monjuvi, Pemazyre, Zynyz |
| Lilly USA, LLC | $1,077.91 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $835.45 | 2021-2023 | Padcev, Tukysa |
| Eisai INC. | $773.80 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $732.53 | 2021-2025 | Opdivo |
| Pfizer INC. | $729.85 | 2021-2025 | |
| Celgene Corporation | $677.51 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $642.98 | 2021-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $534.69 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $503.83 | 2022-2025 | |
| Gilead Sciences, INC. | $440.12 | 2023-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $399.48 | 2021-2025 | Enhertu, Calquence |
| Puma Biotechnology, INC. | $347.04 | 2021-2025 | Nerlynx |
| Astellas Pharma US INC | $346.09 | 2021-2025 | Vyloy |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariele Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.